HRP20240013T1 - Menotropin za liječenje neplodnosti - Google Patents
Menotropin za liječenje neplodnosti Download PDFInfo
- Publication number
- HRP20240013T1 HRP20240013T1 HRP20240013TT HRP20240013T HRP20240013T1 HR P20240013 T1 HRP20240013 T1 HR P20240013T1 HR P20240013T T HRP20240013T T HR P20240013TT HR P20240013 T HRP20240013 T HR P20240013T HR P20240013 T1 HRP20240013 T1 HR P20240013T1
- Authority
- HR
- Croatia
- Prior art keywords
- treatment
- day
- preparation
- use according
- patient
- Prior art date
Links
- 208000000509 infertility Diseases 0.000 title claims 2
- 230000036512 infertility Effects 0.000 title claims 2
- 231100000535 infertility Toxicity 0.000 title claims 2
- 210000002459 blastocyst Anatomy 0.000 claims 6
- 108010005853 Anti-Mullerian Hormone Proteins 0.000 claims 2
- 102100030173 Muellerian-inhibiting factor Human genes 0.000 claims 2
- 208000036878 aneuploidy Diseases 0.000 claims 2
- 239000000868 anti-mullerian hormone Substances 0.000 claims 2
- 230000003322 aneuploid effect Effects 0.000 claims 1
- 231100001075 aneuploidy Toxicity 0.000 claims 1
- 239000002474 gonadorelin antagonist Substances 0.000 claims 1
- 229940121381 gonadotrophin releasing hormone (gnrh) antagonists Drugs 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 230000016087 ovulation Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/42—Gynaecological or obstetrical instruments or methods
- A61B17/425—Gynaecological or obstetrical instruments or methods for reproduction or fertilisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0604—Whole embryos; Culture medium therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0608—Germ cells
- C12N5/0609—Oocytes, oogonia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Developmental Biology & Embryology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pregnancy & Childbirth (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Surgery (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
Claims (7)
1. Pripravak koji sadrži menotropin za upotrebu u liječenju neplodnosti kod pacijenta kako bi se time pospješio razvoj euploidnih blastocista za budući prijenos blastociste na pacijenta, pri čemu liječenje uključuje:
identificiranje pacijenta koji ima razinu serumskog antimullerovog hormona (AMH) ≥ 5,2 ± 0,5 ng/ml i broj antralnih folikula (AFC) ≥ 10 u oba jajnika zajedno prije tretmana/stimulacije; i
davanje doze od ili doze koja je ekvivalentna 75 do 300 IU hMG dnevno od 1. do najmanje 5. dana liječenja.
2. Pripravak za upotrebu prema zahtjevu 1, naznačen time što liječenje za poticanje razvoja euploidnih blastocista za budući prijenos blastociste povećava udio/postotak euploidnih blastocista u usporedbi s udjelom/postotkom aneuploidnih blastocista i/ili smanjuje stopu aneuploidije.
3. Pripravak za upotrebu prema bilo kojem prethodnom zahtjevu, naznačen time što liječenje nadalje obuhvaća:
davanje hCG-a za poticanje ovulacije.
4. Pripravak za upotrebu prema bilo kojem prethodnom zahtjevu, naznačen time što je menotropin visoko pročišćeni menotropin (HP-hMG).
5. Pripravak za upotrebu prema bilo kojem prethodnom zahtjevu, naznačen time što liječenje obuhvaća korak davanja pacijentu doze od ili doze koja je ekvivalentna 75 do 200 IU HP-hMG dnevno od 1. dana do najmanje 5. dana liječenja.
6. Pripravak za upotrebu prema bilo kojem prethodnom zahtjevu, naznačen time što liječenje obuhvaća korak davanja pacijentu doze od, ili doze ekvivalentne 150 IU HP-hMG po danu od 1. dana do najmanje 5. dana liječenja.
7. Pripravak za upotrebu prema bilo kojem prethodnom zahtjevu, naznačen time što sadrži daljnji korak davanja antagonista GnRH 6. dana liječenja.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562121113P | 2015-02-26 | 2015-02-26 | |
| US201562121131P | 2015-02-26 | 2015-02-26 | |
| EP15157661 | 2015-03-04 | ||
| EP15185191 | 2015-09-15 | ||
| EP16709720.3A EP3261661B1 (en) | 2015-02-26 | 2016-02-25 | Menotropin for treating infertility |
| PCT/EP2016/053934 WO2016135221A1 (en) | 2015-02-26 | 2016-02-25 | Methods of treating infertility |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240013T1 true HRP20240013T1 (hr) | 2024-03-29 |
Family
ID=56787937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240013TT HRP20240013T1 (hr) | 2015-02-26 | 2016-02-25 | Menotropin za liječenje neplodnosti |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US10413592B2 (hr) |
| EP (2) | EP4289477A3 (hr) |
| JP (2) | JP7163027B2 (hr) |
| KR (1) | KR102618298B1 (hr) |
| CN (2) | CN107257690A (hr) |
| AU (1) | AU2016223496B2 (hr) |
| CA (1) | CA2976032A1 (hr) |
| DK (1) | DK3261661T3 (hr) |
| ES (1) | ES2968102T3 (hr) |
| FI (1) | FI3261661T3 (hr) |
| HK (1) | HK1246655A1 (hr) |
| HR (1) | HRP20240013T1 (hr) |
| HU (1) | HUE064604T2 (hr) |
| LT (1) | LT3261661T (hr) |
| MA (1) | MA41758B1 (hr) |
| MD (1) | MD3261661T2 (hr) |
| MX (1) | MX2017010320A (hr) |
| PH (1) | PH12017501493A1 (hr) |
| PL (1) | PL3261661T3 (hr) |
| RS (1) | RS65096B1 (hr) |
| RU (1) | RU2723098C2 (hr) |
| SG (1) | SG11201706693QA (hr) |
| SI (1) | SI3261661T1 (hr) |
| WO (1) | WO2016135221A1 (hr) |
| ZA (1) | ZA201705489B (hr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2968102T3 (es) | 2015-02-26 | 2024-05-07 | Ferring Bv | Menotropina para el tratamiento de la infertilidad |
| ES2904787T3 (es) | 2017-09-01 | 2022-04-06 | Ferring Bv | Composición para la estimulación ovárica controlada |
| CN109602394B (zh) * | 2018-12-12 | 2020-01-17 | 北京大学第三医院 | 评估受试者卵巢储备功能的系统 |
| CN110491505B (zh) * | 2019-08-22 | 2021-06-01 | 北京大学第三医院（北京大学第三临床医学院） | 预测受试者卵巢刺激过程中获得的卵母细胞数量的系统 |
| TW202210096A (zh) * | 2020-05-29 | 2022-03-16 | 荷蘭商菲林公司 | 治療不育症之方法 |
| EP3932419A1 (en) * | 2020-06-29 | 2022-01-05 | Ferring B.V. | Methods of treating infertility |
| MX2023000034A (es) * | 2020-06-26 | 2023-02-02 | Ferring Bv | Hp-hmg para su uso en el tratamiento de la infertilidad en una paciente con sindrome de ovario poliquistico. |
| KR102498267B1 (ko) | 2021-01-13 | 2023-02-13 | 주식회사 아이웍스 | 마이크로버블 생성 혼합 수중 에어레이터 회전분사 조립체 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4725579A (en) | 1985-02-21 | 1988-02-16 | Serono Laboratories, Inc. | Method of in vitro fertilization by a unique combination of gonadotropins |
| DE60034117T2 (de) | 1999-04-16 | 2007-12-13 | Instituto Massone S.A. | Verfahren zur herstelllung von gonadotropin-zusammensetzungen |
| YU21104A (sh) * | 2001-09-12 | 2006-08-17 | Applied Research Systems Ars Holding N.V. | Upotreba hcg i lh u kontrolisanoj hiperstimulaciji ovarijuma |
| US20140235540A1 (en) * | 2008-05-20 | 2014-08-21 | Norbert Gleicher | Androgen and gonadotropin treatment in females |
| RU2466724C1 (ru) * | 2011-05-31 | 2012-11-20 | Фатима Якубовна Богатырева | Способ лечения больных бесплодием, обусловленным поликистозом яичников, яичникового генеза на фоне хронического и острого воспаления органов малого таза |
| US9404908B2 (en) * | 2013-04-29 | 2016-08-02 | The Board of Truestees of the Leland Stanford Junior University | Non-invasive imaging to the blastocyst stage for the detection of human embryonic aneuploidy |
| ES2968102T3 (es) | 2015-02-26 | 2024-05-07 | Ferring Bv | Menotropina para el tratamiento de la infertilidad |
-
2016
- 2016-02-25 ES ES16709720T patent/ES2968102T3/es active Active
- 2016-02-25 LT LTEPPCT/EP2016/053934T patent/LT3261661T/lt unknown
- 2016-02-25 DK DK16709720.3T patent/DK3261661T3/da active
- 2016-02-25 CA CA2976032A patent/CA2976032A1/en active Pending
- 2016-02-25 CN CN201680011732.8A patent/CN107257690A/zh active Pending
- 2016-02-25 HU HUE16709720A patent/HUE064604T2/hu unknown
- 2016-02-25 MA MA41758A patent/MA41758B1/fr unknown
- 2016-02-25 EP EP23195379.5A patent/EP4289477A3/en active Pending
- 2016-02-25 FI FIEP16709720.3T patent/FI3261661T3/fi active
- 2016-02-25 MD MDE20180026T patent/MD3261661T2/ro unknown
- 2016-02-25 PL PL16709720.3T patent/PL3261661T3/pl unknown
- 2016-02-25 CN CN202111138328.6A patent/CN113769069A/zh active Pending
- 2016-02-25 HR HRP20240013TT patent/HRP20240013T1/hr unknown
- 2016-02-25 KR KR1020177026095A patent/KR102618298B1/ko active IP Right Grant
- 2016-02-25 SI SI201631789T patent/SI3261661T1/sl unknown
- 2016-02-25 RS RS20240071A patent/RS65096B1/sr unknown
- 2016-02-25 SG SG11201706693QA patent/SG11201706693QA/en unknown
- 2016-02-25 US US15/053,116 patent/US10413592B2/en active Active
- 2016-02-25 JP JP2017545238A patent/JP7163027B2/ja active Active
- 2016-02-25 EP EP16709720.3A patent/EP3261661B1/en active Active
- 2016-02-25 AU AU2016223496A patent/AU2016223496B2/en active Active
- 2016-02-25 RU RU2017131129A patent/RU2723098C2/ru active
- 2016-02-25 MX MX2017010320A patent/MX2017010320A/es unknown
- 2016-02-25 WO PCT/EP2016/053934 patent/WO2016135221A1/en active Application Filing
-
2017
- 2017-08-14 ZA ZA2017/05489A patent/ZA201705489B/en unknown
- 2017-08-17 PH PH12017501493A patent/PH12017501493A1/en unknown
-
2018
- 2018-05-11 HK HK18106172.7A patent/HK1246655A1/zh unknown
-
2019
- 2019-08-29 US US16/555,688 patent/US11351228B2/en active Active
-
2020
- 2020-08-20 JP JP2020139478A patent/JP7157108B2/ja active Active
- 2020-12-10 US US17/117,643 patent/US11679145B2/en active Active
-
2023
- 2023-05-05 US US18/144,046 patent/US20240009278A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20240013T1 (hr) | Menotropin za liječenje neplodnosti | |
| HRP20210722T1 (hr) | Pripravak za kontroliranu stimulaciju jajnika | |
| MX2019010994A (es) | Metodos para tratar enfermedades y trastornos mediados por el complemento. | |
| BR112019003753A2 (pt) | sistema e método para terapia médica controlada | |
| HRP20151444T4 (hr) | Sredstva za liječenje i postupci liječenja dlbcl | |
| MX2016011832A (es) | Reduccion de los niveles o la actividad de las células t reguladoras sistémicas para el tratamiento de enfermedad y lesión del sistema nervioso central (snc). | |
| MX2020013557A (es) | Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y métodos de uso del mismo. | |
| MX2015012559A (es) | Novedosos fármacos de alta penetración y sus composiciones para el tratamiento de enfermedades de parkinson. | |
| MX2020005906A (es) | Marcadores fenotipicos para terapia celular y metodos relacionados. | |
| HRP20192246T1 (hr) | Marker za poremećaje kisele sfingomijelinaze i njegova uporaba | |
| MX2017011633A (es) | Uso de composiciones que contienen peptido inhibidor de mk2 para tratar cancer de pulmon de celulas no pequeñas con las mismas. | |
| BR112018013063A2 (pt) | combinação terapêutica inibidora de bromodomínio e proteína extra-terminal | |
| NZ744233A (en) | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack | |
| EA201992612A1 (ru) | Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения эндометриоза | |
| HRP20210406T1 (hr) | Postupci za povećanje volumena prisilnog izdisaja kod astmatičara uporabom benralizumaba | |
| MX2015009055A (es) | Forma de dosificacion oral de liberacion sostenida gastro retentiva de un secuestrante de acido biliar. | |
| BR112018000383A2 (pt) | métodos para tratar hcv | |
| NZ769954A (en) | Syringe devices for use in an emergency | |
| MX2019005342A (es) | Tratamiento de enfermedades del sistema nervioso central (snc) con estimulantes de guanilato ciclas solubles (sgc). | |
| RU2017128296A (ru) | Композиция для лечения бесплодия | |
| WO2016140910A3 (en) | Compositions and methods of using anti-mullerian hormone for treatment of infertility | |
| MX2019012660A (es) | Metodo para tratar cancer empleando un inhibidor de proteina de linfoma de celulas b 2 (bcl-2) en forma conjunta con una radioinmunoterapia con emision de particulas alfa. | |
| BR112015001859A2 (pt) | tratamento de inflamação utilizando serelaxina | |
| BR112015012497A2 (pt) | combinações farmacêuticas | |
| HRP20211802T1 (hr) | Pripravak za kontroliranu stimulaciju jajnika |